C s dng c cho ngi b mn kinh khng
Zepbound (tirzepatide) and Wegovy (semaglutide) are designed for adults who are overweight or have obesity, and both have proven benefits, but they also have important differences that are important to understand
They represent a paradigm shift in obesity treatment that demands structured semaglutide training for physicians
Many patients see 15-20% reduction in body weight over several months
If semaglutide suppresses appetite significantly, it could reduce your overall food intake, making it harder to get the nutrients you need
Together, these actions: Reduce appetite and food cravings Help patients feel full longer Lower blood sugar levels in people with type 2 diabetes Because of these combined effects, semaglutide has become a powerful tool not only for diabetes care but also for long-term weight loss